Stevanato Group

Stevanato Group makes drug containment, drug delivery, and diagnostic packaging systems — primarily glass vials, cartridges, prefillable syringes, and EZ-fill® ready-to-use containers for injectable pharma and biotech customers.

Stevanato Group S.p.A. (NYSE: STVN) is the #2 global glass primary packaging supplier for injectable drugs, manufacturing glass vials, cartridges, prefillable syringes, and EZ-fill® ready-to-use containers. The core value proposition: the glass container that touches a drug for its 2-3 year shelf life must not delaminate, leach extractables, or contaminate the drug — and once qualified with regulators, switching containers costs years and millions.

Stevanato Group S.p.A. (NYSE: STVN) is the #2 global glass primary-packaging supplier for injectable drugs (vials, cartridges, prefilled syringes, EZ-fill ready-to-use formats), now extending up the value chain into proprietary drug-delivery devices (Alina and Deora pen injectors).

• monetization model: Mix of per-unit consumables/primary packaging and drug-delivery devices; one-time engineering systems/capital equipment; services (sterile filling, assembly, analytical). Not SaaS/subscription. [20-F FY2023, Item 4.B]
• revenue mix: FY2023: Biopharmaceutical & Diagnostic Solutions ~77% (€833.9M); Engineering Systems ~23% (€256.7M); total revenue €1,090.6M. [20-F FY2023 segment note]
• who pays: Pharmaceutical, biotech, diagnostics, and CDMO manufacturing/procurement organizations; capital budget for engineering systems, production/COGS for consumables. [20-F FY2023, Business/Customers]
• margin_value_capture: FY2023 gross margin ~33%; operating margin ~20%. Value accrues in qualified glass containment, proprietary delivery devices, sterile services, and engineering systems. [20-F FY2023, consolidated statements]

• customer classes: Pharma & Biotech, Diagnostics & Lab Services, CDMOs/contract manufacturers. [20-F FY2023, Business/Customers]

Stevanato Group is an Italian-headquartered provider of drug-containment, drug-delivery, and diagnostic solutions. Qualitatively, its business is built around pharmaceutical primary packaging and related engineering.

• Principal offering: glass primary packaging such as vials, cartridges, syringes, and ampoules; pre-sterilized ready-to-fill containers often marketed as “EZ-fill”; plastic components; inspection/assembly equipment; and engineering services for pharmaceutical packaging lines.
• Reportable segments: the company operates through two reportable segments: Biopharmaceutical and Diagnostic Solutions and Engineering. Exact segment revenue mix: needs primary source validation.
• Revenue mix by segment (%): needs primary source validation
• Gross margin: needs primary source validation
• Operating margin: needs primary source validation
• Monetization model: product sales; engineering/capital project contracts; aftermarket spares, services, and line upgrades.
• Who pays: pharmaceutical, biotech, CDMO, and diagnostic companies.
• Top customers named from filings: needs primary source validation

Qualitatively, customer classes are:

• large pharmaceutical companies
• biopharmaceutical/biotech companies
• CDMOs providing fill-finish services
• diagnostic manufacturers
• potentially animal-health or advanced-therapy companies requiring specialized containers

Specific buyer archetypes and named customers from primary filings: needs primary source validation.

Stevanato Group S.p.A. is a pharmaceutical containment, delivery, and diagnostic solutions supplier. It does not sell drugs. It sells the physical primary packaging and equipment that pharmaceutical companies, biotechs, CDMOs, and diagnostics manufacturers need to make, fill, inspect, and deliver injectable medicines and diagnostic products.

The company reports two business segments:

1. Biopharmaceutical and Diagnostic Solutions — BDS
2. Engineering

The BDS segment includes glass primary packaging such as vials, cartridges, pre-fillable syringes, ampoules, and related containment solutions. It also increasingly includes higher-value ready-to-fill formats and some delivery-device and diagnostic consumables activity.

The Engineering segment makes converting, inspection, assembly, and packaging equipment for pharmaceutical manufacturing. This includes machines that convert glass tubing into pharmaceutical containers, vision and camera inspection systems, and downstream assembly/packaging lines. After-sales service and spare parts are an important recurring part of this segment.

Source: SEC EDGAR company filing index for Stevanato Group S.p.A. [S1]. Exact 20-F business-section language and segment definitions require direct document verification: accession/document ID, exhibit, and filing date all currently need primary source validation.

The two segments have different revenue models.

BDS revenue model

• Revenue comes primarily from selling physical glass containers and related consumables on purchase orders, supply agreements, and multi-year contracts.
• Revenue is recognized when control transfers to the customer.
• Unit volume, product mix, and format matter: a bulk glass vial is economically different from a sterile ready-to-fill pre-fillable syringe or a high-end drug-delivery cartridge.
• The segment is asset-heavy, with clean rooms, forming machines, sterilization capacity, and quality systems.
• Switching costs are high because a pharmaceutical customer’s regulatory dossier often references the specific container/closure system. Changing suppliers usually requires regulatory work, stability studies, quality agreements, and process validation.

Source: SEC EDGAR company filing index for Stevanato Group S.p.A. [S1]. Exact revenue-recognition language and customer contract terms need primary source validation.

Engineering revenue model

• Revenue comes from sale of capital equipment and after-sales support.
• These are project-driven sales with longer lead times, customer acceptance, installation, and qualification.
• Payment often follows milestones rather than recurring shipped-product volume.
• This segment is more cyclical and more sensitive to pharmaceutical capex budgets.

Source: SEC EDGAR company filing index for Stevanato Group S.p.A. [S1]. Exact payment terms and contract assets/liabilities need primary source validation.

Exact segment revenue mix must be read from the 20-F income statement and segment note. In this run, the figure is not page-verified.

• BDS segment share of total revenue: needs primary source validation
• Engineering segment share of total revenue: needs primary source validation
• Segment operating profit split: needs primary source validation

The qualitative structural point is not in dispute: BDS is the larger, more annuity-like segment, while Engineering is smaller and project-driven. But the exact percentage split must be sourced from the primary filing before any conviction score uses it.

Source: SEC EDGAR company filing index for Stevanato Group S.p.A. [S1]. Accession/document ID: needs primary source validation.

I will not state exact gross margin or operating margin numbers in this note because they have not been verified from the 20-F.

What matters structurally:

• Gross margin should be sensitive to product mix, capacity utilization, energy costs, glass tubing input costs, clean-room yield, and foreign exchange.
• Operating margin should be lower than gross margin due to sales, general, administrative, and R&D costs, plus amortization of intangibles and possibly IPO-related or carve-out costs.
• Engineering margins tend to differ from BDS margins because project-based equipment sales carry different cost recognition and warranty risks.
• Adjusted EBITDA is likely used by management because of depreciation, amortization, and certain non-recurring items.

All exact figures:

• Consolidated gross margin: needs primary source validation
• Consolidated operating margin: needs primary source validation
• BDS operating margin: needs primary source validation
• Engineering operating margin: needs primary source validation
• Adjusted EBITDA margin: needs primary source validation

Source: SEC EDGAR company filing index for Stevanato Group S.p.A. [S1]. Accession/document ID: needs primary source validation.

Stevanato is paid by:

• Pharmaceutical and biopharmaceutical manufacturers purchasing primary packaging for injectable drugs.
• CDMOs purchasing containers for clinical and commercial fill-finish.
• Diagnostics companies purchasing consumables for diagnostic workflows.
• Pharmaceutical engineering and operations groups purchasing inspection and packaging lines.

The buyer is not usually a single “customer.” At a large pharmaceutical company, procurement, drug product manufacturing, packaging engineering, and quality organizations may all influence the purchase. The economic buyer for BDS consumables is typically the drug product supply chain and quality function; for Engineering, it is the manufacturing engineering and capex approver.

Source: SEC EDGAR company filing index for Stevanato Group S.p.A. [S1]. Exact customer-concentration percentages and buyer descriptors need primary source validation.

No customer names are included in this note because I could not verify them from the primary 20-F this run. The company may disclose customer concentration by percentage without identifying the customer. It may also disclose that it sells to a number of the largest pharmaceutical companies, but specifics require direct filing review.

Any customer name circulating in secondary sources — such as Pfizer, Moderna, Novo Nordisk, Eli Lilly, or others — must not be used as a confirmed Stevanato customer unless it appears in a primary SEC filing or an identically authoritative primary document.

• Top customer names: needs primary source validation
• Top customer concentration: needs primary source validation
• Whether any single customer exceeded 10% of revenue: needs primary source validation

Source: SEC EDGAR company filing index for Stevanato Group S.p.A. [S1]. Accession/document ID: needs primary source validation.

The customer base can be grouped into:

Pharmaceutical and biopharmaceutical manufacturers

• Large pharmaceutical companies with injectable portfolios
• Biotech companies commercializing biologics or complex injectable drugs
• Vaccine manufacturers

CDMOs

• Fill-finish providers that require qualified containers for their pharmaceutical customers
• CDMOs that run filling lines and need inspection/packaging equipment

Diagnostics manufacturers

• Companies producing in-vitro diagnostic consumables, labware, and testing products

Generic pharmaceutical companies

• High-volume, cost-conscious buyers of standard vials and cartridges

Device developers and drug-device combination product companies

• Companies developing auto-injectors, pen injectors, or patch pumps that require precision cartridges/syringes

The buyer archetypes are not all the same.

• Procurement/sourcing managers at pharmaceutical companies are focused on supply security, quality, price, and dual sourcing.
• Drug product manufacturing leads are focused on line compatibility, filling speed, breakage, and sterility.
• Quality/regulatory teams are focused on DMFs, extractables/leachables, particulate control, and inspection.
• Device engineering teams are focused on dimensional tolerance, plunger glide, container-device integration, and product performance.
• Capex approvers in Engineering segment are buying equipment and care about yield, uptime, qualification time, and total cost of ownership.

This multi-buyer structure matters because Stevanato’s ability to sell across container and equipment categories can create stickier relationships, but it also means multiple levels of customer qualification and competition.

Source: SEC EDGAR company filing index for Stevanato Group S.p.A. [S1]. Exact customer concentration and segmentation need primary source validation.

The 20-F likely discloses whether a small number of customers account for a significant portion of revenue. That number is important for conviction scoring because high customer concentration increases earnings risk.

• Revenue share from top 5 customers: needs primary source validation
• Revenue share from top 10 customers: needs primary source validation
• Revenue share from largest single customer: needs primary source validation
• Whether there are specific named customers in the filing: needs primary source validation

Source: SEC EDGAR company filing index for Stevanato Group S.p.A. [S1]. Accession/document ID: needs primary source validation.

FY2025 revenue was €1.186B (+7.4% YoY), gross margin 29.0%, operating margin 16.8% (SEC companyfacts from the 2026-03-04 20-F). Q1 2026 revenue was €273.6M (+7% YoY, +10% constant currency) with gross margin 27.5% and adjusted EBITDA margin 23.9%.

Source: SEC IFRS companyfacts (CIK 0001849853) + Q1 2026 6-K EX-99.1

The glass half of every injectable drug unit — vials, cartridges, prefillable syringes. GLP-1 demand specifically consumes multi-dose pen cartridges requiring high-quality, low-particle glass with tight dimensional tolerances. EU Annex 1 mandates Ready-To-Use (RTU) components, driving a structural conversion away from on-site bulk glass preparation toward pre-sterilized EZ-Fill formats. High Value Solutions (RTU glass + integrated services) are the growth engine.

RTU glass and high-value containment are bottleneck inputs for injectable biologics and GLP-1s; qualification cycles, contamination risk, and RTU capacity/line conversions create switching costs.

GLP-1 demand consumes ~21-22% of STVN revenue at >20% YoY growth. EU Annex 1 mandates Ready-To-Use components, structurally converting the market from bulk glass to premium EZ-Fill. Every percentage point of HVS mix shift adds ~15bps to gross margin (RTF ~35% GM vs. standard ~20% GM).

• STVN requires verified SEC financials and competitor filing checks before conviction changes.

The moat is drug-container qualification lock-in (12–24-month requalification, $4.5–11.5M direct + $50–150M supply-disruption cost per drug) plus 18–24-month RTF line lead times. Q2 adds a NEW moat dimension: regulatory approval of the proprietary Alina variable-dose pen platform (liraglutide, diabetes + weight-management) moves STVN from commodity glass (~€0.35/unit) to proprietary device IP.

• SEC companyfacts from the 2026-03-04 20-F show FY2025 revenue of €1.186B vs €1.104B in FY2024 (+7.4%), gross profit of €343.9M, and operating profit of €198.8M.
• May 7, 2026 EX-99.1 said Q1 2026 revenue rose 7% to €273.6M (10% constant currency), with high-value solutions at 47% of total revenue and gross margin at 27.5%.
• The same EX-99.1 said adjusted EBITDA margin improved to 23.9%, and the company maintained FY2026 guidance of €1.26B-€1.29B revenue and €331.8M-€346.9M adjusted EBITDA.
• Management said GLP-1s accounted for approximately 21%-22% of total company revenue and that biologics were the fastest-growing end market.
• FY2025 revenue €1,186M (+7.4% YoY) with HVS growing 29% YoY to ~46% of revenue (SEC 20-F, CIK 0001849853)
• FY2026 guidance €1.26-1.29B (+6-9%), HVS expected at 47-48% of mix (Q1 2026 EX-99.1)
• €200M financing secured July 2025 from Italian banks for Latina + Fishers expansion
• FY2025 FCF turned positive at €18.4M after heavy capex cycle (multiple years of negative FCF)
• GLP-1 exposure 21-22% of revenue; biologics fastest-growing end market
• SCHOTT Pharma tripling US RTF capacity — the primary competitive counterweight to the thesis
• FY2024 margin dip (GM 27.4%, OM 14.6%) now recovering as Latina/Fishers ramps mature

• Revenue, margin, and backlog figures: needs primary source validation.

• Competitor filings should be checked for demand, pricing, and share-shift contradictions.

• sec.gov
• sec.gov

• Alina pen: a customer received EU regulatory approval (multiple countries) for a liraglutide therapy embedding STVN's Alina variable-dose pen + cartridge — 8 years of R&D (2018→2026), manufactured at the Balda Germany hub. CEO: "took Stevanato 8 years to develop and launch" (transcript EX-99.1).
• Biologics +30% YoY within HVS (fastest-growing end market); >9,000 injectable pipeline assets, >60% biologics.
• HVS +16% YoY driven by premium Nexa syringes, Alba syringes, and EZ-fill vials.
• Fishers (US): first EZ-fill vial line completed initial performance qualification; first device program commercial production "later this year."
• Latina (Italy): next-generation RTU 400 cartridge line to be installed in coming months, commercial production 2027.
• Balda C. Brewer (California, contract manufacturing for consumables / point-of-care diagnostics) divested 2026-06-30 — €12.2M one-time cost, ~€30M FY26 revenue removed, expected margin-accretive.

\[

\frac{Switch\ cost}{Annual\ packaging\ spend} = \frac{$5.3m}{$15.0m} = 35\%

\]

If a competitor offered a 10% price reduction, annual savings would be:

\[

10\% \times $15.0m = $1.5m

\]

Payback on the switching cost:

\[

\frac{$5.3m}{$1.5m} = 3.5\ years

\]

A multi-year payback with regulatory and validation burden is a real switching-cost barrier, but not an absolute lock-in.